FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 190 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Can Being Exposed to Wildfire Smoke Affect Your Cancer Risk? February 1, 2024 Berry Recipes August 14, 2020 Increasing Education About Cancer Screening and Prevention in Kazakhstan May 11, 2021 What to Know About Cancer Clinical Trial Matching Programs March 14, 2023 Load more HOT NEWS Treatment for Oropharyngeal Cancer: Investigating Ways to Do Less Harm FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma For People with Cancer, Are Steroids the Best Treatment for Breathing... When Used Together, Chemo and Cardiac Drug Improve Chances of Cancer...
